Allogeneic hematopoietic stem cell transplantation (HSCT) is a very specialized, resource-intense, and costly medical procedure, and among the procedures with the greatest impact on hospital costs [1] [2] [3] . With the marked increase in the number of HSCTs, it is important not only to assess clinical outcomes, but also to address the economic consequences. There is emerging knowledge of the costs of HSCT, but a lack of comprehensive studies of the health effects in terms of quality-adjusted life years (QALY) gained. We, therefore, aimed to study cost-utility of HSCT in a population-based cohort of Norwegian children, adolescents, and young adults. The cost per QALY is a commonly used measure in priority setting in the healthcare sector and is estimated based on both the quality and length of life gained as a result of a treatment and the costs associated with the treatment (Fig. 1) .
We measured the quality of life among long-term survivors of HSCT who participated in a cross-sectional study (the AlloSS-young study) conducted at Oslo University Hospital (OUH) between August 2014-February 2016, primarily aiming to identify late effects after allogeneic HSCT performed in childhood or young adulthood (pending publication). Eligible participants were long-term survivors who underwent their first allogeneic HSCT before 30 years of age, were over 16 years at time of survey (born before August 1998), and had at least 5 years observation time from HSCT (HSCT between December 1974-August 2009). All diagnoses were included except mucopolysaccharidosis type 1 as these patients may have multisystem morbidity as part of their primary disease. The participants in AlloSS-young underwent comprehensive clinical investigations and/or completed a questionnaire survey, which included the Short-Form 36 used to measure health-related quality of life [4] . We used the algorithm described by Brazier and Roberts to convert the answers from the SF-36 to a single score between 0 (dead) and 1(perfect quality of life) [5] [6] [7] .
We also performed a retrospective review of all children and young adults transplanted at OUH, which included both long-term survivors and deceased patients, who otherwise met the eligibility criteria of the cross-sectional study (HSCT < 30 years of age, born before August 1998, HSCT before August 2009), to estimate survival among all transplanted patients (pending publication). The Kaplan-Meier method was used to estimate probabilities of overall survival (OS), defined as time from HSCT to death from any cause. The estimated mean life expectancy was calculated based on the observed survival rates among the patients in the retrospective study.
A previous prospective study of transplantation-related costs conducted at OUH, provided detailed information on costs associated with pre-transplant procedures and transplantation costs through 1 year post-transplantation [8] . This study by Mishra et al., concluded that the mean cost of HSCT in adults was €108,237 (€132,169; 2016-currency). The major drivers of costs were related to personnel/length of hospital stay with the costs associated with unrelated donors, medications and blood components as other important factors. To assess whether the results of the cost study could be applied to the entire study period and to children, we compared data from the cost study with data from the retrospective study and hospital charts for a representative selection of years (1996, 2002, and 2008) . The length of hospital stay were the same (p = 0.13) among children (mean 55.3 days, SD 56.7) and adults (mean 55.6 days, SD 31.8). No major cost demanding changes were identified. Compared to adults, the costs related to medication and blood components were considered to be lower in children due to lower body weight, but the costs related to personnel were higher due the need of more personnel resources in the children's department. The percentage of unrelated donors was similar in the cohort study as compared to the cost study. Thus, we regard the costs of HSCT disclosed by Mishra et al., as the best cost estimate for the entire cohort.
All statistical analyses were performed using Stata 14 (StataCorp, College Station, TX, USA).
As part of the AlloSS-young cross-sectional study, 108 of 157 eligible long-term survivors (69%) completed the SF-36 questionnaire. The transformed responses to the SF-36 gave a score for average life quality of 0.77, which is 15% lower than for a reference population of similar age (0.90) [4] .
We included 286 consecutive patients in the retrospective study. An overview of patient characteristics and transplantation outcome is presented in Table 1 . Altogether 130 patients died during follow-up. The probability of OS for the entire study period was 60.1% and 57.5% for 5-year survival and 10-year survival, respectively. The estimated mean life expectancy was calculated to be 19.0 years. This represents the life-years gained since HSCT is a treatment offered to patients with otherwise low or no probability of cure. The mean transplantation costs were €132,169 (2016-currency). Based on the assumption that the reported SF-36 score was representative for the entire study period, we multiplied this score with the number of expected life-years to get the average QALY gained, which was 14.6 years (19 years x 0.77 score) as result of HSCT, giving an estimated cost per QALYs of €9053 (€132,169/14.6 QALY).
Considerations of cost-effectiveness will become more important given the rapidly increasing healthcare costs, and accurate knowledge of cost-utility will be an essential aid in health economic decision-making. The Norwegian Health authorities often use a threshold of about €64,000 per QALY to determine whether a new drug or treatment will be reimbursed or not. Moreover, newly proposed guidelines suggest that for severe diseases the threshold should be €88,000 per QALY [9] . In the UK, National Institute for Health and Care Excellence (NICE) is believed to have a threshold of about £30,000 per QALY, while in North America, a threshold of about US$50000 per QALY has been suggested [10, 11] . Thus, the costs of HSCT in our study are far below present governmental thresholds.
The cost-utility analysis was based on the patients' observed survival, their self-reported quality of life after transplantation, and on a detailed prospective study of the costs. There are, to our knowledge, few studies on the costutility of HSCT. However, Matthes-Martin et al. [12] , reported in a retrospective study cost per QALY ranging from €1553 to €24,031, the costs increased with increasing transplantation-related mortality risk. We believe that our study provides more accurate estimation of the cost per QALY as we, opposed to Matthes-Martin et al., who assumed that transplanted children would survive for 60 years and with a perfect quality of life, measured the actual quality of life among long-term survivors and calculated the mean life expectancy among patients in the cohort study. By limiting the calculation to the observed survival rates among the reviewed patients, we underestimate the life years gained as the majority of the patients were still young and alive at the end of the study period with long-life expectancy, and hence, the actual cost per QALY will be lower than reported by us. The study at OUH by Mishra et al., included pretransplant procedures and the transplantation through oneyear follow up, which should ensure that the major costs were included [3] . Although studies on transplantationrelated cost are not directly comparable due to heterogeneity, the transplantation costs demonstrated by Mishra et al., is in line with the studies that have been previously published.
There are limitations to our study including the heterogeneity of the patients and its retrospective design. The cost-utility analysis is based on an average responding patient. A more detailed approach would require several measurements of each patient (including quality of life at different points in time) and a separate calculation of the cost per QALY for each patient. Finally, although hospital costs make up most of the healthcare costs for this type of treatment, there are costs associated with out-patient care and with primary care that are not accounted for. Still, the cost/benefit-ratio is far below the threshold set by the government when all the major costs are included.
In conclusion, our study shows that that HSCTs performed in the period 1974-2009 were cost-effective with a cost per QALY which was substantially lower than current governmental thresholds. Cost-utility of allogeneic hematopoietic stem cell transplantation
